Nancy Hong Ph.D Overview
- Company
- Archmont Biophar...
- Primary Position
-
President
- Primary Industry
-
Healthcare
- Med. Deal Size
-
- Med. Valuation
-
Nancy Hong Ph.D General Information
Biography
Dr. Nancy Hong serves as President at Archmont Biopharma. Dr. Hong served as Managing Director at RiverVest Venture Partners. She served as Board Member at Bluejay Therapeutics. She also served as Board member at Akrevia Therapeutics and SeQure DX. She served as Board Member of Xilio Therapeutics. She served as Board Member at Scout Bio. She serves as Principal at BioMed Ventures. She joined BioMed Ventures in April 2013. Previously she was a senior analyst at Forward Ventures and advised biotech and pharma companies, including the Genomics Institute of the Novartis Research Foundation, entering new areas of research. From 2002 to 2006 Dr. Hong was a senior scientist at Phenomix where she directed a scientific group, managed pharma collaborations, and evaluated research opportunities. Dr. Hong trained in the areas of immunology and oncology, and she was a postdoctoral fellow of The Leukemia & Lymphoma Society with Nobel-laureate Dr. J. Michael Bishop at the University of California, San Francisco. Dr. Hong received a Bachelor of Science with honors in biology from the California Institute of Technology and a Ph.D. in Molecular and Cellular Biology from the University of California at Berkeley. She served as Board Member at Biolinq.
Contact Information
Address
- 101 South Hanley Road
- Suite 1850
- Saint Louis, MO 63105
- United States
Nancy Hong Ph.D Positions (1)
Firm name | Firm type | Title | Location | Industry | Since |
---|---|---|---|---|---|
Archmont Biopharma | Company | President | Saint Louis, MO | Drug Discovery |
Nancy Hong Ph.D Lead Partner on Deals (9)
Nancy Hong Ph.D has been the lead partner on 9 deals. Their latest deal was with Biolinq, a monitoring equipment company. The deal was made for on 17-Oct-2022.
Company | Deal Date | Deal Type | Deal Size | Deal Status | Industry | Location |
---|---|---|---|---|---|---|
Biolinq | 17-Oct-2022 | Later Stage VC (Series B) | Completed | Monitoring Equipment | San Diego, CA | |
Bluejay Therapeutics | 16-Aug-2022 | Completed | Drug Discovery | San Mateo, CA | ||
Scout Bio | 19-Oct-2021 | Completed | Biotechnology | Philadelphia, PA | ||
Bluejay Therapeutics | 17-Jun-2021 | Completed | Drug Discovery | San Mateo, CA | ||
SeQure DX | 02-Apr-2021 | Completed | Biotechnology | Waltham, MA | ||
Xilio Therapeutics | 23-Feb-2021 | Completed | Drug Discovery | Waltham, MA | ||
Xilio Therapeutics | 02-Mar-2020 | Completed | Drug Discovery | Waltham, MA | ||
Scout Bio | 29-Mar-2019 | Early Stage VC (Series B) | Completed | Biotechnology | Philadelphia, PA | |
Scout Bio | 27-Feb-2018 | Early Stage VC (Series A) | Completed | Biotechnology | Philadelphia, PA |
Nancy Hong Ph.D Network (116)
Board Members (60)
Name | Company | Representing | Location | From |
---|---|---|---|---|
Tiffany Yu | Xilio Therapeutics | F-Prime Capital | Waltham, MA | |
Daniel Curran | Xilio Therapeutics | Takeda Ventures | Waltham, MA | |
Xilio Therapeutics | MRL Ventures Fund | Waltham, MA | ||
SeQure DX | SeQure DX | Waltham, MA | ||
Bluejay Therapeutics | Self | San Mateo, CA |
Portfolio Executives (50)
Name | Company | Role | Deal date | Location |
---|---|---|---|---|
David Arida | Biolinq | Chief Operating Officer | 17-Oct-2022 | San Diego, CA |
Andrew Woodmansee | Biolinq | Vice President, Legal Affairs | 17-Oct-2022 | San Diego, CA |
Biolinq | Chief Executive Officer & Board Member | 17-Oct-2022 | San Diego, CA | |
Biolinq | Co-Founder, President & Co-Chief Operating Officer | 17-Oct-2022 | San Diego, CA | |
Biolinq | Co-Founder, Chief Technology Officer & President | 17-Oct-2022 | San Diego, CA |
Fund Team Members (6)
Name | Investor | Fund | Fund Location |
---|---|---|---|
Niall O'Donnell Ph.D | RiverVest Venture Partners | RiverVest Venture Fund V | Saint Louis, MO |
Niall O'Donnell Ph.D | RiverVest Venture Partners | Archer Seed Fund | Saint Louis, MO |
RiverVest Venture Partners | Saint Louis, MO | ||
RiverVest Venture Partners | Saint Louis, MO | ||
RiverVest Venture Partners | Saint Louis, MO |
Nancy Hong Ph.D Affiliated Funds (4)
Fund | Investor | Fund Type | Status | Vintage | Size | Dry Powder | IRR | IRR Quartile |
---|---|---|---|---|---|---|---|---|
Archer Seed Fund | RiverVest Venture Partners | Venture Capital - Early Stage | Closed | 2016 | ||||
RiverVest Venture Fund V | RiverVest Venture Partners | Venture Capital - Early Stage | Closed | 2020 | ||||
RiverVest Venture Fund III | RiverVest Venture Partners | Venture Capital - Early Stage | Fully Invested | 2014 | ||||
RiverVest Venture Fund IV | RiverVest Venture Partners | Venture Capital - Early Stage | Closed | 2018 |
Nancy Hong Ph.D FAQs
-
Who is Nancy Hong Ph.D?
Dr. Nancy Hong serves as President at Archmont Biopharma.
-
How much does Nancy Hong Ph.D typically invest?
Nancy Hong Ph.D's median deal size is
. -
What is Nancy Hong Ph.D’s main position?
Nancy Hong Ph.D’s primary position is President.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »